Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Prashanth Gouda

Prashanth Gouda

National University of Science and Technology, Oman

Title: High-frequency oscillatory ventilation: What is New?

Biography

Biography: Prashanth Gouda

Abstract

High-frequency oscillatory ventilation (HFOV) was developed as a new technique of ventilation technique in late seventies, twenty years after the invention of the first artificial respirator. In this mode of ventilation, tidal volumes are smaller than anatomical dead space and respiratory rate is supra-physiological. Animal models showed that HFOV was able to achieve adequate gas exchange with lower inflation pressure at the alveoli with a relatively constant volume above the functional residual capacity leading to significant mitigation of preterm lung injury in the form of volutrauma, barotrauma and atelectrauma. However, early clinical trials failed to demonstrate consistently, favorable results in terms of pulmonary outcome when compared to standard modes of ventilation. Subsequent emergence of volume guarantee (VG) in combination with HFOV made it possible to play with frequency and tidal volume. The addition of VG setting to the ventilator can help to optimize ventilation (stable carbon dioxide removal) as well as oxygenation. Currently, attempts are being made to determine the highest frequency and the lowest tidal volume according to gestational age and birth weight to define a new lung protection strategy. Indeed HFOV with or without VG is increasingly used in preterm infants with respiratory failure. Current evidence suggests that early HFOV could reduce lung injury in combination with an open lung strategy. Nasal HFOV has come up as the newest mode of high-frequency ventilation in neonates. The latest evidence suggests that following surfactant administration, nasal HFOV could be superior to nasal CPAP in preterm infants with moderate to severe RDS without increase in adverse effects.